Nucleic Acid Quantitation Kits

Global Nucleic Acid Quantitation Kits Market to Reach US$2.3 Billion by 2030

The global market for Nucleic Acid Quantitation Kits estimated at US$1.7 Billion in the year 2024, is expected to reach US$2.3 Billion by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. DNA Quantitation Kits, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the RNA Quantitation Kits segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$456.5 Million While China is Forecast to Grow at 8.8% CAGR

The Nucleic Acid Quantitation Kits market in the U.S. is estimated at US$456.5 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$467.2 Million by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Nucleic Acid Quantitation Kits Market – Key Trends & Drivers Summarized

Is Precision Quantitation the Missing Link in High-Throughput Genomics?

Nucleic acid quantitation kits play a pivotal role in molecular biology workflows by enabling accurate measurement of DNA and RNA concentrations in research, diagnostics, therapeutics, and forensic applications. These kits—typically based on absorbance (UV spectrophotometry), fluorescence, or colorimetric assays—are essential for quality control in sample preparation prior to PCR, qPCR, next-generation sequencing (NGS), microarray analysis, and gene expression profiling. As demand for high-integrity nucleic acid inputs increases across genomics-driven fields, quantitation kits have become indispensable for ensuring reproducibility, sensitivity, and downstream assay fidelity.

In clinical genomics and diagnostic laboratories, nucleic acid quantification is a frontline process for evaluating sample purity and suitability. High-throughput laboratories handling biopsy-derived RNA, cfDNA, or viral RNA require fast, reliable, and scalable quantification tools with high sensitivity and low sample consumption. Kits employing fluorescence-based dyes such as PicoGreen®, RiboGreen®, or Qubit® fluorophores are favored for their ability to selectively bind nucleic acids with minimal interference from contaminants like phenol, proteins, or salts. In parallel, miniaturized platforms integrated with microfluidic devices are enabling real-time quantitation within automated sample-to-answer systems.

Why Is the Market Shifting Toward Ultra-Sensitive and Workflow-Compatible Quantitation Tools?

The growing complexity of genomics and transcriptomics experiments is amplifying the need for precise nucleic acid measurement at increasingly low concentrations. Applications such as single-cell sequencing, liquid biopsy analysis, and low-input RNA-seq require quantitation methods capable of detecting nanogram or picogram-level DNA/RNA with high specificity. This is steering the market toward fluorescence- and dye-based kits that offer selective binding, broad dynamic range, and compatibility with multiplex workflows. These kits support critical decision-making in library preparation, normalization, and fragment analysis for NGS and CRISPR editing platforms.

Workflow integration is another key demand driver. Quantitation kits are increasingly designed for compatibility with robotic liquid handlers, multi-well plate formats, and LIMS software, enabling seamless incorporation into automated laboratory pipelines. Time-to-result, reagent stability, and minimal hands-on time are becoming crucial features in core facilities and diagnostic centers. Manufacturers are also innovating with lyophilized reagents, multiplexing capacity, and combined quantification-purity assays to meet the requirements of both high-throughput environments and field-based research. Cloud-based data logging and instrument connectivity are further enhancing quality assurance and traceability in regulated genomics workflows.

How Are New Application Frontiers and Regulatory Frameworks Driving Innovation?

The expansion of molecular diagnostics, personalized medicine, and synthetic biology is redefining the applications of nucleic acid quantitation. In diagnostics, the growing use of nucleic acid amplification tests (NAATs) for infectious diseases and oncology is prompting the adoption of rapid and clinically validated quantitation kits. In cell and gene therapy, where dosing and vector quality depend on accurate nucleic acid input, quantitation kits serve as critical control tools. Regulatory agencies such as the FDA and EMA are also emphasizing analytical validation of quantitation steps in diagnostic test kits and therapeutic workflows.

In agricultural biotechnology, food traceability, and biosurveillance, portable quantitation kits with simplified protocols are enabling nucleic acid analysis in non-laboratory settings. Kits compatible with isothermal amplification or CRISPR-based diagnostics are being developed to support field-based and point-of-care applications. Meanwhile, academic and industrial researchers working in epigenetics, metagenomics, and non-coding RNA studies require kits that are optimized for fragmented, degraded, or chemically modified nucleic acids. These requirements are accelerating innovation in reagents, buffer systems, and signal amplification techniques to enhance accuracy and adaptability.

What’s Driving the Accelerated Growth of the Nucleic Acid Quantitation Kits Market?

The growth in the nucleic acid quantitation kits market is driven by a combination of surging demand for molecular diagnostics, expanding applications in high-throughput sequencing, and rising investments in biopharma R&D. The explosion of RNA- and DNA-based therapeutics—including mRNA vaccines, antisense oligonucleotides, and gene editing therapies—has created new imperatives for precise nucleic acid quality control. Biopharmaceutical companies and contract research organizations (CROs) are investing in standardized quantitation kits to meet regulatory expectations and ensure batch-to-batch consistency in therapeutic development.

In parallel, the democratization of genomics is fueling kit adoption in academic labs, diagnostic startups, and personalized health companies. As the cost of sequencing falls and new applications emerge, nucleic acid quantitation is becoming a routine and recurring need across diverse sectors. Global health programs focused on pathogen surveillance, antimicrobial resistance, and pandemic preparedness are also driving procurement of field-deployable quantitation kits for decentralized molecular testing.

With innovations in detection chemistry, miniaturization, and software integration, nucleic acid quantitation kits are evolving from standalone reagents into workflow enablers. As the life sciences ecosystem continues to scale in volume and complexity, these kits are expected to see sustained demand growth and technological advancement across clinical, research, agricultural, and biomanufacturing domains.

SCOPE OF STUDY:

The report analyzes the Nucleic Acid Quantitation Kits market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (DNA Quantitation Kits, RNA Quantitation Kits); Application (Hospital Laboratories, Reference Laboratories, Academic Research Laboratories, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• AAT Bioquest, Inc.
• Abcam plc
• Agilent Technologies
• Analytik Jena AG
• Bio-Rad Laboratories
• Biotium, Inc.
• Enzo Life Sciences
• GE Healthcare
• Invitrogen (Thermo Fisher Scientific)
• Merck KGaA
• New England Biolabs
• PerkinElmer, Inc.
• Promega Corporation
• Qiagen N.V.
• Roche Diagnostics
• Sigma-Aldrich (Merck)
• Thermo Fisher Scientific
• TriLink BioTechnologies
• Vector Laboratories
• VWR International

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.